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Abstract Contrast enhancement by microbubble infusion
has proven its applicability in the field of diagnostic
ultrasound. Recent studies also indicate a therapeutic effect
of the combined use of ultrasound and microbubbles.
Results from animal studies demonstrate that diagnostic
ultrasound in combination with intravenous microbubbles
can dissolve thrombi. So far, this effect has never been tested
in patients with an acute ST-elevation myocardial infarction
(STEMI). We recently launched a pilot study in acute STEMI
patients to assess safety, feasibility and efficacy of the
treatment in this patient group with transthoracic three-
dimensional diagnostic ultrasound and intravenous micro-
bubbles immediately after prehospital thrombolysis, but prior
to primary percutaneous coronary intervention.
Keywords Ultrasound.Microbubbles.Myocardial
infarction.Facilitated PCI
Background
The introduction of microbubbles as an ultrasound contrast
agent in 1968 increased the diagnostic potential of
ultrasound without major drawback [1]. Nowadays, micro-
bubbles are widely accepted as a clinical agent in diagnostic
ultrasound. These microbubbles are smaller in size than
erythrocytes and thus capable of passing through the
smallest capillaries. Their acoustic properties make it
possible to improve the quality of the local image.
Depending on the peak acoustic pressure produced by a
source the microbubble scatters in a unique manner. Under
influence of low acoustic peak pressures, i.e. mechanical
index (MI) below 0.1, the microbubble oscillates linearly,
thus enhancing the backscatter. Increasing the peak pressure
(MI 0.1–1.0) induces the microbubble to oscillate non-
linearly resulting in harmonic backscatter. Peak pressures
with an MI above 1.0 lead to bubble disruption causing
transient nonlinear harmonic backscattering. These different
types of acoustic behavior can be used for several clinical
applications [2].
More recently, it was also shown that combining micro-
bubbles with ultrasound has therapeutic possibilities.
Ultrasound alone has proven its therapeutic potential in
the field of thromboembolic processes. In vitro and in vivo
studies have revealed that the presence of ultrasound
increased clot lysis, particularly in low frequency ultra-
sound with high power [3]. It was implicated that cavita-
tional effects were the main working mechanism behind
these results. Cavitation is the creation, vibration and
destruction of small bubbles in a medium. Since it was
known that microbubbles lower the threshold for acoustic
cavitation it was assumed that the addition of microbubbles
during ultrasound application could enhance clot lysis even
further. Tachibana and Tachibana were the first to prove this
principle in vitro [4].
Although cavitation is believed to be the driving force
behind this effect, based on the occurrence of micro-
streaming and shear stress [5], it is also assumed that the
generation of reactive oxygen species in endothelial cells
[6] and local temperature rise after the microbubble
collapse [7] play a pivotal role. However, the full
mechanism remains to be resolved [8].
J. Slikkerveer (*)
Department of Cardiology and Institute of Cardiovascular Research,
VU University Medical Center,
Room 4D194, De Boelelaan 1117,
1081 HVAmsterdam, the Netherlands
e-mail: j.slikkerveer@vumc.nl
G. Veen: Y. Appelman: N. van Royen:O. Kamp
Department of Cardiology and Institute of Cardiovascular Research,
VU University Medical Center,
Amsterdam, the Netherlands
Neth Heart J (2011) 19:200–205
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studies have confirmed enhanced clot lysis (Table 1). These
studies focused on the macrovascular system and applied
different ultrasound frequencies and acoustic pressures. It is
known that low frequency ultrasound has a better penetra-
tion and thus potentially leads to a better thrombolytic
result. Nevertheless, since high frequency ultrasound is
already commercially available in the diagnostic field
because of its better spatial resolution, the first phase II
trial in the neurological field by the CLOTBUST inves-
tigators has been performed using high frequency ultra-
sound. They randomly assigned 126 stroke patients to
receive continuous ultrasound or placebo following treat-
ment with intravenous tissue-type plasminogen activator
(t-PA) within 3 h after the onset of symptoms. Their results
show a significant increase of complete recanalisation in the
ultrasound group compared with placebo [9]. In a spin-off
study in stroke patients, microbubbles were added on top of
ultrasound and t-PA. This led to a further enhancement of
ultrasound augmented thrombolysis, resulting in increased
complete recanalisation rates [10].
Currently, the first choice of treatment in patients with
acute ST-elevation myocardial infarction (STEMI) is
primary percutaneous coronary intervention (PCI) [11].
When PCI is not available, the administration of thrombo-
lytics within 12 h after onset of symptoms is the optimal
approach. Nevertheless, the recanalisation rate after throm-
bolysis is very low and is also related to more haemorrhagic
complications [12].
Until now the combination of diagnostic ultrasound,
intravenous microbubbles and thrombolytic therapy has
never been tested in STEMI patients admitted for primary
PCI. Therefore, we have initiated the first pilot study to
determine the safety, feasibility and efficacy of three-
dimensional (3D) ultrasound and microbubbles to increase
the epicardial reperfusion rates in patients with their first
acute STEMI presenting in the hospital for primary PCI.
The Sonolysis trial
We plan to include patients between 18 and 80 years of age
diagnosed with their first acute STEMI based on a proximal
occlusion of the infarct-related artery. In order to increase
the likelihood of a proximal occlusion our inclusion criteria
consist of a sum of ST elevation of 6 mm or more in
combined leads and 1 mm or more ST-elevation in lead
V4R in case of an inferior infarction. Patients with clinical
instability, previous Q-wave myocardial infarction, contra-
indication to alteplase, known pulmonary hypertension and
known allergy to Luminity® are excluded [13].
Patients are randomised in either a placebo group or a
group that receives the ultrasound contrast agent Luminity®.
Randomisation takes place when the ambulance announces a
patient with an eligible STEMI. This announcement is done
through the unique Lifenet system in the Amsterdam region
[14]. A 12-lead ECG of a patient with chest pain is taken by
ambulance personnel and sent to a computer in the
coronary care unit of the hospital. There, the cardiology
resident on call consults the intervention cardiologist and
together they check the ECG for inclusion criteria. If the
patient is eligible for the study, the ambulance personnel are
informed and they check for contraindications to alteplase
using a questionnaire. If there are no contraindications
patients are pre-treated in the ambulance with a loading
dose of aspirin 500 mg iv, heparin 5000 IU iv, and a single
bolus alteplase 50 mg iv.
On arrival at the hospital, patients receive, after oral
informed consent, either placebo (i.e. 50 ml saline 0.9%)
without ultrasound, or the ultrasound contrast agent
Luminity® during simultaneously pulsatile 3D ultrasound
application using the diagnostic ultrasound machine iE33
(Philips, Best, the Netherlands) with a frequency of
1.6 MHz and a MI of 1.18. The matrix 3D probe will be
used to obtain 3D full volume images of the aortic root in
the parasternal short-axis view to ascertain that the
proximal parts of the epicardial coronary artery system are
encompassed within the target zone. In order to ensure that
the microbubbles replenish around the occlusion of the
infarct-related artery, ultrasound is applied intermittently
(5 s on, 5 s off). The microbubbles are infused intrave-
nously for 15 min using a continuous infusion pump at a
rate of 200 ml/h.
After 15 min, patients are immediately transported to the
catheterisation laboratory where they undergo an emergency
angiogram to assessTIMI flowandsubsequentlyprimaryPCI
is carried out when necessary.
Bi om ar ke rsan dEC Gar eob ta in edev er y3hdu ri ngth efi rs t
24 h. After 2 to 9 days and after 4 months follow-up, a two-
dimensionalechocardiogramandadelayedcontrast-enhanced
MRI are conducted to measure left ventricular volumes and
ejection fraction, wall motion score and scar mass.
Primary endpoint of the study is the TIMI flow grade to
document patency of the culprit vessel.
Safety is assessed by documenting adverse events and
serious (cardiac) adverse events during treatment and follow-
up of 4 months. Death, cardiogenic shock, ventricular
fibrillation, sustained ventricular tachycardia, major bleeding
(e.g. when packed cells are needed) and recurrent myocardial
infarction are marked as serious cardiac adverse events.
Feasibility is based on the successful accomplishment of
the treatment protocol prior to PCI.
Fig. 1 shows a case example of a patient who received
active therapy with diagnostic 3D ultrasound and intrave-
nous microbubbles. An acute STEMI of the anterior wall is
visible on the ECG obtained in the ambulance. The sum of
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At the end of ultrasound treatment the ECG showed an
accelerated idioventricular rhythm (not shown) and the
patient noticed chest pain relief. On the emergency
angiogram TIMI III flow of the left descending artery was
seen, prior to PCI. Since there was still a more than 70%
stenosis, PCI was performed. ECG at 60 min after primary
PCI shows more than 70% ST resolution and maximum
CK-MB was 104 μg/l. No adverse events occurred during
treatment and at 4 months follow-up.
Future application
No-reflow
The aim of this pilot study is to assess safety, feasibility and
efficacy of the treatment with diagnostic 3D ultrasound and
intravenous microbubbles in the setting of an acute STEMI
withpre-treatmentoflow-dosethrombolyticsintheambulance,
focusing on the epicardial reperfusion rate under influence of
ultrasound and microbubbles compared with placebo.
Interestingly, until recently, research was focused on
recanalisation of the thrombotic occluded epicardial artery.
In an invivo pigstudy itwas observed that themicrovascular
flow improved after treatment of the risk area despite
absence of epicardial reperfusion [15]. Preliminary data in
a second pig experiment by the same group using 3D
ultrasound confirmed these results [16]. Not only does the
combination of ultrasound and microbubbles have an effect
on the epicardial coronary artery system, it might also have
a positive effect on microvascular flow after acute STEMI
and thus serve as an adjuvant therapy in patients with no-
reflow. A possible explanation might be the local release of
nitric oxide under influence of ultrasound, resulting in an
increased capillary diameter and thus improvement of local
perfusion [17]. Furthermore, the earlier mentioned temper-
ature rise and creation of microjets under influence of
cavitation might also influence the pathogenetic mechanism
of no-reflow in the microvasculature [18].
Drug and gene delivery
On top of the enhanced thrombolytic effect, the combina-
tion of ultrasound and microbubbles has also proven its
potential in the field of drug and gene delivery. The local
destruction of microbubbles under the influence of ultra-
sound results in the enhanced uptake of dextran molecules.
Fig. 1 Example of a patient. The top ECG shows an acute anterior
wall infarction. The patient received active treatment and subsequently
underwent angiography which revealed a TIMI III flow with more
than 70% occlusion of the proximal LAD. A stent was placed and the
ECG 60 min after primary PCI showed more than 70% ST resolution
Neth Heart J (2011) 19:200–205 203It was shown by Meijering et al. that pore formation as well as
endocytosis arethe twomainmechanisms ofuptake [19]. This
implicates possible pathways for local drug and gene
delivery. Especially, in combination with the option to target
the microbubbles to increase the local concentration in the
area of interest, this might enhance the potential effect of
stem cell therapy in the setting of an acute MI [20]. In a
mouse MI model, Fujii and colleagues have managed a
successful local delivery of vascular endothelial growth factor
(VEGF) and stem cell factor (SCF) incubated in micro-
bubbles using ultrasound for local destruction, resulting in
improved myocardial perfusion and ventricular function [21].
Conclusion
This first Sonolysis study might stimulate future research
and technical innovations to improve the treatment of
STEMI patients to obtain more patency at an earlier stage in
the ambulance. Furthermore, the combination of ultrasound
and intravenous microbubbles might also be useful in the
setting of primary PCI for treatment of no-reflow.
Thus, the application of ultrasound and microbubbles in
the field of cardiology are very widespread and hold great
opportunities for future therapeutic interventions.
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